$5.11 1.4%
EDIT Stock Price vs. AI Score (Last 150 days)
Data gathered: June 22

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company which is developing therapies based on CRISPR–Cas9 gene editing technology. Editas is based in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Editas Medicine
Price $5.11
Target Price Sign up
Volume 9,040,000
Market Cap $417M
Year Range $5.04 - $11.11
Dividend Yield 0%
Revenue per Employee $314,115
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '241.1M19M-18M-62M-62M-0.760
Q4 '2362M14M47M-19M-22M-0.230
Q3 '235.3M15M-9.7M-45M-45M-0.550
Q2 '232.9M17M-14M-40M-44M-0.560
Q1 '238.3M23M-15M-49M-51M-0.710

Insider Transactions View All

Mei Baisong filed to sell 141,032 shares at $5.5.
June 6 '24
O'Neill Gilmore Neil filed to sell 315,279 shares at $5.5.
June 6 '24
Lucera Erick filed to sell 116,829 shares at $5.6.
May 22 '24
Hopfield Jessica filed to buy 67,700 shares at $5.6.
May 14 '24
O'Neill Gilmore Neil filed to sell 327,470 shares at $9.4.
March 5 '24

What is the Market Cap of Editas Medicine?

The Market Cap of Editas Medicine is $417M.

How Many People Work at Editas Medicine?

As of our latest update, Editas Medicine employed approximately 226 people worldwide. However, it's important to note that Editas Medicine's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Editas Medicine's revenue per employee?

$314,115. To calculate Editas Medicine's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Editas Medicine?

Currently, the price of one share of Editas Medicine stock is $5.11.

How can I analyze the EDIT stock price chart for investment decisions?

The EDIT stock price chart above provides a comprehensive visual representation of Editas Medicine's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Editas Medicine shares. Our platform offers an up-to-date EDIT stock price chart, along with technical data analysis and alternative data insights.

Does EDIT offer dividends to its shareholders?

As of our latest update, Editas Medicine (EDIT) does not offer dividends to its shareholders. Investors interested in Editas Medicine should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Editas Medicine?

Some of the similar stocks of Editas Medicine are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.